Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4(+) T cells to reduce the latent HIV(+) cell reservoir

Chimeric Antigen Receptor (CAR)-redirected T cells show great efficacy in the patient-specific therapy of hematologic malignancies. Here, we demonstrate that a DARPin with specificity for CD4 specifically redirects and triggers the activation of CAR engineered T cells resulting in the depletion of C...

Descripción completa

Detalles Bibliográficos
Autores principales: Patasic, Lea, Seifried, Janna, Bezler, Valerie, Kaljanac, Marcell, Schneider, Irene C., Schmitz, Heike, Tondera, Christiane, Hartmann, Jessica, Hombach, Andreas, Buchholz, Christian J., Abken, Hinrich, König, Renate, Cichutek, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568711/
https://www.ncbi.nlm.nih.gov/pubmed/32918599
http://dx.doi.org/10.1007/s00430-020-00692-0
_version_ 1783596580250583040
author Patasic, Lea
Seifried, Janna
Bezler, Valerie
Kaljanac, Marcell
Schneider, Irene C.
Schmitz, Heike
Tondera, Christiane
Hartmann, Jessica
Hombach, Andreas
Buchholz, Christian J.
Abken, Hinrich
König, Renate
Cichutek, Klaus
author_facet Patasic, Lea
Seifried, Janna
Bezler, Valerie
Kaljanac, Marcell
Schneider, Irene C.
Schmitz, Heike
Tondera, Christiane
Hartmann, Jessica
Hombach, Andreas
Buchholz, Christian J.
Abken, Hinrich
König, Renate
Cichutek, Klaus
author_sort Patasic, Lea
collection PubMed
description Chimeric Antigen Receptor (CAR)-redirected T cells show great efficacy in the patient-specific therapy of hematologic malignancies. Here, we demonstrate that a DARPin with specificity for CD4 specifically redirects and triggers the activation of CAR engineered T cells resulting in the depletion of CD4(+) target cells aiming for elimination of the human immunodeficiency virus (HIV) reservoir. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00430-020-00692-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7568711
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-75687112020-10-19 Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4(+) T cells to reduce the latent HIV(+) cell reservoir Patasic, Lea Seifried, Janna Bezler, Valerie Kaljanac, Marcell Schneider, Irene C. Schmitz, Heike Tondera, Christiane Hartmann, Jessica Hombach, Andreas Buchholz, Christian J. Abken, Hinrich König, Renate Cichutek, Klaus Med Microbiol Immunol Original Investigation Chimeric Antigen Receptor (CAR)-redirected T cells show great efficacy in the patient-specific therapy of hematologic malignancies. Here, we demonstrate that a DARPin with specificity for CD4 specifically redirects and triggers the activation of CAR engineered T cells resulting in the depletion of CD4(+) target cells aiming for elimination of the human immunodeficiency virus (HIV) reservoir. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00430-020-00692-0) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-09-12 2020 /pmc/articles/PMC7568711/ /pubmed/32918599 http://dx.doi.org/10.1007/s00430-020-00692-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Investigation
Patasic, Lea
Seifried, Janna
Bezler, Valerie
Kaljanac, Marcell
Schneider, Irene C.
Schmitz, Heike
Tondera, Christiane
Hartmann, Jessica
Hombach, Andreas
Buchholz, Christian J.
Abken, Hinrich
König, Renate
Cichutek, Klaus
Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4(+) T cells to reduce the latent HIV(+) cell reservoir
title Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4(+) T cells to reduce the latent HIV(+) cell reservoir
title_full Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4(+) T cells to reduce the latent HIV(+) cell reservoir
title_fullStr Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4(+) T cells to reduce the latent HIV(+) cell reservoir
title_full_unstemmed Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4(+) T cells to reduce the latent HIV(+) cell reservoir
title_short Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4(+) T cells to reduce the latent HIV(+) cell reservoir
title_sort designed ankyrin repeat protein (darpin) to target chimeric antigen receptor (car)-redirected t cells towards cd4(+) t cells to reduce the latent hiv(+) cell reservoir
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568711/
https://www.ncbi.nlm.nih.gov/pubmed/32918599
http://dx.doi.org/10.1007/s00430-020-00692-0
work_keys_str_mv AT patasiclea designedankyrinrepeatproteindarpintotargetchimericantigenreceptorcarredirectedtcellstowardscd4tcellstoreducethelatenthivcellreservoir
AT seifriedjanna designedankyrinrepeatproteindarpintotargetchimericantigenreceptorcarredirectedtcellstowardscd4tcellstoreducethelatenthivcellreservoir
AT bezlervalerie designedankyrinrepeatproteindarpintotargetchimericantigenreceptorcarredirectedtcellstowardscd4tcellstoreducethelatenthivcellreservoir
AT kaljanacmarcell designedankyrinrepeatproteindarpintotargetchimericantigenreceptorcarredirectedtcellstowardscd4tcellstoreducethelatenthivcellreservoir
AT schneiderirenec designedankyrinrepeatproteindarpintotargetchimericantigenreceptorcarredirectedtcellstowardscd4tcellstoreducethelatenthivcellreservoir
AT schmitzheike designedankyrinrepeatproteindarpintotargetchimericantigenreceptorcarredirectedtcellstowardscd4tcellstoreducethelatenthivcellreservoir
AT tonderachristiane designedankyrinrepeatproteindarpintotargetchimericantigenreceptorcarredirectedtcellstowardscd4tcellstoreducethelatenthivcellreservoir
AT hartmannjessica designedankyrinrepeatproteindarpintotargetchimericantigenreceptorcarredirectedtcellstowardscd4tcellstoreducethelatenthivcellreservoir
AT hombachandreas designedankyrinrepeatproteindarpintotargetchimericantigenreceptorcarredirectedtcellstowardscd4tcellstoreducethelatenthivcellreservoir
AT buchholzchristianj designedankyrinrepeatproteindarpintotargetchimericantigenreceptorcarredirectedtcellstowardscd4tcellstoreducethelatenthivcellreservoir
AT abkenhinrich designedankyrinrepeatproteindarpintotargetchimericantigenreceptorcarredirectedtcellstowardscd4tcellstoreducethelatenthivcellreservoir
AT konigrenate designedankyrinrepeatproteindarpintotargetchimericantigenreceptorcarredirectedtcellstowardscd4tcellstoreducethelatenthivcellreservoir
AT cichutekklaus designedankyrinrepeatproteindarpintotargetchimericantigenreceptorcarredirectedtcellstowardscd4tcellstoreducethelatenthivcellreservoir

Ejemplares similares